전이성 폐선암 치료 시장 규모, 점유율, 동향, 산업 분석 보고서 : 치료별, 최종사용자별, 지역별 - 시장 예측(2025-2034년)

The global metastatic lung adenocarcinoma treatment market size is expected to reach USD 14.17 billion by 2034, according to a new study by Polaris Market Research. The report "Metastatic Lung Adenocarcinoma Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, and Others), End User (Hospitals, Specialty Clinics, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The metastatic lung adenocarcinoma treatment market growth can be attributed to advancements in targeted therapies and immunotherapies that are significantly improving patient outcomes, increasing prevalence of lung cancer, and the rising demand for personalized medicine.

The development of novel treatment options, particularly those targeting specific genetic mutations such as EGFR and ALK, would offer opportunities for the market in the coming years. Trends indicate a growing focus on combination therapies and biomarker-driven approaches to enhance treatment efficacy. Overall, the market is expected to expand as pharmaceutical companies invest heavily in research and development to meet the evolving needs of this patient population.

Metastatic Lung Adenocarcinoma Treatment Market Report Highlights:

Based on treatment, the immunotherapy segment dominates the market due to its ability to provide durable responses and improved survival rates. The targeted therapy segment is also seeing significant growth, particularly in patients with identifiable genetic mutations such as EGFR.

In terms of end users, the hospital segment remains the largest shareholder in the metastatic lung adenocarcinoma treatment market, driven by the availability of advanced treatment options and comprehensive care facilities. The specialty clinics segment is growing rapidly, catering to the increasing demand for focused and personalized cancer treatment.

North America dominates the global metastatic lung adenocarcinoma treatment market, attributed to the presence of major pharmaceutical companies and advanced healthcare infrastructure. Asia Pacific is the fastest-growing market, propelled by rising cancer incidence rates and increasing healthcare investments.

AstraZeneca, Roche, Merck & Co., Bristol-Myers Squibb, Pfizer, Novartis, Eli Lilly and Company, Amgen, Sanofi, Boehringer Ingelheim, Takeda Pharmaceutical Company, Johnson & Johnson, AbbVie, Bayer, and GlaxoSmithKline are among the key players in the metastatic lung adenocarcinoma treatment market.

Polaris Market Research has segmented the metastatic lung adenocarcinoma treatment market report on the basis of treatment, end user, and region:

By Treatment Outlook (Revenue - USD Billion, 2020-2034)

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Radiation Therapy
• Others

By End User Outlook (Revenue - USD Billion, 2020-2034)

• Hospitals
• Specialty Clinics
• Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

• North America
• US
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Netherlands
• Russia
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Malaysia
• South Korea
• Indonesia
• Australia
• Vietnam
• Rest of Asia Pacific
• Middle East & Africa
• Saudi Arabia
• UAE
• Israel
• South Africa
• Rest of Middle East & Africa
• Latin America
• Mexico
• Brazil
• Argentina
• Rest of Latin America

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Metastatic Lung Adenocarcinoma Treatment Market Insights

• 4.1. Metastatic Lung Adenocarcinoma Treatment Market - Market Snapshot
• 4.2. Metastatic Lung Adenocarcinoma Treatment Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increased Focus on Targeted Therapies
    • 4.2.1.2. Advancements in Immunotherapy
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Low Survival Rates
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Metastatic Lung Adenocarcinoma Treatment Market Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Metastatic Lung Adenocarcinoma Treatment Market, by Treatment

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
• 5.3. Chemotherapy
  • 5.3.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
• 5.4. Targeted Therapy
  • 5.4.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
• 5.5. Immunotherapy
  • 5.5.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
• 5.6. Therapy
  • 5.6.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Radiation Therapy, by Region, 2020-2034 (USD Billion)
• 5.7. Others
  • 5.7.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Metastatic Lung Adenocarcinoma Treatment Market, by End User

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
• 6.3. Hospitals
  • 6.3.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Hospitals, by Region, 2020-2034 (USD Billion)
• 6.4. Specialty Clinics
  • 6.4.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Specialty Clinics, by Region, 2020-2034 (USD Billion)
• 6.5. Others
  • 6.5.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Metastatic Lung Adenocarcinoma Treatment Market, by Geography

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Metastatic Lung Adenocarcinoma Treatment Market Assessment, By Geography, 2020-2034 (USD Billion)
• 7.3. Metastatic Lung Adenocarcinoma Treatment Market - North America
  • 7.3.1. North America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • 7.3.2. North America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.3.3. Metastatic Lung Adenocarcinoma Treatment Market - U.S.
    • 7.3.3.1. U.S.: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.3.3.2. U.S.: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.3.4. Metastatic Lung Adenocarcinoma Treatment Market - Canada
    • 7.3.4.1. Canada: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.3.4.2. Canada: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
• 7.4. Metastatic Lung Adenocarcinoma Treatment Market - Europe
  • 7.4.1. Europe: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • 7.4.2. Europe: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.4.3. Metastatic Lung Adenocarcinoma Treatment Market - UK
    • 7.4.3.1. UK: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.4.3.2. UK: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.4.4. Metastatic Lung Adenocarcinoma Treatment Market - France
    • 7.4.4.1. France: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.4.4.2. France: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.4.5. Metastatic Lung Adenocarcinoma Treatment Market - Germany
    • 7.4.5.1. Germany: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.4.5.2. Germany: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.4.6. Metastatic Lung Adenocarcinoma Treatment Market - Italy
    • 7.4.6.1. Italy: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.4.6.2. Italy: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.4.7. Metastatic Lung Adenocarcinoma Treatment Market - Spain
    • 7.4.7.1. Spain: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.4.7.2. Spain: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.4.8. Metastatic Lung Adenocarcinoma Treatment Market - Netherlands
    • 7.4.8.1. Netherlands: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.4.8.2. Netherlands: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.4.9. Metastatic Lung Adenocarcinoma Treatment Market - Russia
    • 7.4.9.1. Russia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.4.9.2. Russia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.4.10. Metastatic Lung Adenocarcinoma Treatment Market - Rest of Europe
    • 7.4.10.1. Rest of Europe: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.4.10.2. Rest of Europe: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
• 7.5. Metastatic Lung Adenocarcinoma Treatment Market - Asia Pacific
  • 7.5.1. Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • 7.5.2. Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.5.3. Metastatic Lung Adenocarcinoma Treatment Market - China
    • 7.5.3.1. China: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.5.3.2. China: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.5.4. Metastatic Lung Adenocarcinoma Treatment Market - India
    • 7.5.4.1. India: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.5.4.2. India: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.5.5. Metastatic Lung Adenocarcinoma Treatment Market - Malaysia
    • 7.5.5.1. Malaysia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.5.5.2. Malaysia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.5.6. Metastatic Lung Adenocarcinoma Treatment Market - Japan
    • 7.5.6.1. Japan: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.5.6.2. Japan: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.5.7. Metastatic Lung Adenocarcinoma Treatment Market - Indonesia
    • 7.5.7.1. Indonesia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.5.7.2. Indonesia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.5.8. Metastatic Lung Adenocarcinoma Treatment Market - South Korea
    • 7.5.8.1. South Korea: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.5.8.2. South Korea: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.5.9. Metastatic Lung Adenocarcinoma Treatment Market - Australia
    • 7.5.9.1. Australia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.5.9.2. Australia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.5.10. Metastatic Lung Adenocarcinoma Treatment Market - Rest of Asia Pacific
    • 7.5.10.1. Rest of Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.5.10.2. Rest of Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
• 7.6. Metastatic Lung Adenocarcinoma Treatment Market - Middle East & Africa
  • 7.6.1. Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • 7.6.2. Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.6.3. Metastatic Lung Adenocarcinoma Treatment Market - Saudi Arabia
    • 7.6.3.1. Saudi Arabia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.6.3.2. Saudi Arabia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.6.4. Metastatic Lung Adenocarcinoma Treatment Market - UAE
    • 7.6.4.1. UAE: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.6.4.2. UAE: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.6.5. Metastatic Lung Adenocarcinoma Treatment Market - Israel
    • 7.6.5.1. Israel: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.6.5.2. Israel: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.6.6. Metastatic Lung Adenocarcinoma Treatment Market - South Africa
    • 7.6.6.1. South Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.6.6.2. South Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.6.7. Metastatic Lung Adenocarcinoma Treatment Market - Rest of Middle East & Africa
    • 7.6.7.1. Rest of Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.6.7.2. Rest of Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
• 7.7. Metastatic Lung Adenocarcinoma Treatment Market - Latin America
  • 7.7.1. Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • 7.7.2. Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.7.3. Metastatic Lung Adenocarcinoma Treatment Market - Mexico
    • 7.7.3.1. Mexico: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.7.3.2. Mexico: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.7.4. Metastatic Lung Adenocarcinoma Treatment Market - Brazil
    • 7.7.4.1. Brazil: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.7.4.2. Brazil: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.7.5. Metastatic Lung Adenocarcinoma Treatment Market - Argentina
    • 7.7.5.1. Argentina: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.7.5.2. Argentina: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.7.6. Metastatic Lung Adenocarcinoma Treatment Market - Rest of Latin America
    • 7.7.6.1. Rest of Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.7.6.2. Rest of Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)

8. Competitive Landscape

• 8.1. Expansion and Acquisition Analysis
  • 8.1.1. Expansion
  • 8.1.2. Acquisitions
• 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

• 9.1. AstraZeneca
  • 9.1.1. Company Overview
  • 9.1.2. Financial Performance
  • 9.1.3. Product Benchmarking
  • 9.1.4. Recent Development
• 9.2. Roche
  • 9.2.1. Company Overview
  • 9.2.2. Financial Performance
  • 9.2.3. Product Benchmarking
  • 9.2.4. Recent Development
• 9.3. Merck & Co
  • 9.3.1. Company Overview
  • 9.3.2. Financial Performance
  • 9.3.3. Product Benchmarking
  • 9.3.4. Recent Development
• 9.4. Bristol-Myers Squibb
  • 9.4.1. Company Overview
  • 9.4.2. Financial Performance
  • 9.4.3. Product Benchmarking
  • 9.4.4. Recent Development
• 9.5. Pfizer
  • 9.5.1. Company Overview
  • 9.5.2. Financial Performance
  • 9.5.3. Product Benchmarking
  • 9.5.4. Recent Development
• 9.6. Novartis
  • 9.6.1. Company Overview
  • 9.6.2. Financial Performance
  • 9.6.3. Product Benchmarking
  • 9.6.4. Recent Development
• 9.7. Eli Lilly and Company
  • 9.7.1. Company Overview
  • 9.7.2. Financial Performance
  • 9.7.3. Product Benchmarking
  • 9.7.4. Recent Development
• 9.8. Amgen
  • 9.8.1. Company Overview
  • 9.8.2. Financial Performance
  • 9.8.3. Product Benchmarking
  • 9.8.4. Recent Development
• 9.9. Sanofi
  • 9.9.1. Company Overview
  • 9.9.2. Financial Performance
  • 9.9.3. Product Benchmarking
  • 9.9.4. Recent Development
• 9.10. Boehringer Ingelheim
  • 9.10.1. Company Overview
  • 9.10.2. Financial Performance
  • 9.10.3. Product Benchmarking
  • 9.10.4. Recent Development
• 9.11. Takeda Pharmaceutical Company
  • 9.11.1. Company Overview
  • 9.11.2. Financial Performance
  • 9.11.3. Product Benchmarking
  • 9.11.4. Recent Development